Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/50212
Campo DC Valoridioma
dc.contributor.authorBergmann, Karl Christianen_US
dc.contributor.authorDemoly, Pascalen_US
dc.contributor.authorWorm, Margittaen_US
dc.contributor.authorFokkens, Wytske J.en_US
dc.contributor.authorCarrillo, Teresaen_US
dc.contributor.authorTabar, Ana I.en_US
dc.contributor.authorNguyen, Hélèneen_US
dc.contributor.authorMontagut, Armelleen_US
dc.contributor.authorZeldin, Robert K.en_US
dc.date.accessioned2018-11-24T14:15:56Z-
dc.date.available2018-11-24T14:15:56Z-
dc.date.issued2014en_US
dc.identifier.issn0091-6749en_US
dc.identifier.urihttp://hdl.handle.net/10553/50212-
dc.description.abstractBackground Preliminary studies have suggested the efficacy of sublingual tablets of house dust mite (HDM) extracts in adults with allergic rhinitis. Objectives We sought to assess the efficacy and safety of 2 doses of HDM sublingual tablets over 1 treatment year and the subsequent immunotherapy-free year. Methods Adults with HDM-associated allergic rhinitis were randomized in a double-blind, placebo-controlled study to receive 500 index of reactivity (IR) tablets, 300IR tablets, or placebo administered once daily for 1 year and were followed for the subsequent year. The primary efficacy variable was the Average Adjusted Symptom Score over the year 1 primary period (ie, October 1 to December 31). Symptoms and rescue medication scores, onset of action, patient-reported outcomes, and safety were secondary variables. The same end points were evaluated during the immunotherapy-free year. The primary efficacy end point was analyzed by using analysis of covariance. Results Five hundred nine participants were randomized, and 427 continued in the immunotherapy-free year. Both the 500IR and 300IR HDM sublingual tablets significantly reduced mean Average Adjusted Symptom Scores compared with placebo by −20.2% (P = .0066) and −17.9% (P = .0150), respectively. Efficacy of both doses was maintained during the treatment-free follow-up phase. The onset of action was at 4 months. Participants’ global evaluation of treatment success was significantly higher in the 500IR and 300IR groups compared with the placebo group (P = .0206 and P = .0001, respectively). Adverse events were generally application-site reactions. There were no reports of anaphylaxis. Conclusions Twelve months of treatment with 500IR and 300IR sublingual tablets of HDM allergen extracts was efficacious and well tolerated. Efficacy was maintained during the treatment-free follow-up year.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Allergy and Clinical Immunologyen_US
dc.sourceJournal of Allergy and Clinical Immunology[ISSN 0091-6749],v. 133 (6) , pp. 1608-1614 (Junio 2014)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320701 Alergiasen_US
dc.subject.otherAllergic rhinitisen_US
dc.subject.otherDouble-blinden_US
dc.subject.otherHouse dust mitesen_US
dc.subject.otherPlacebo-controlleden_US
dc.subject.otherSublingual immunotherapy tabletsen_US
dc.titleEfficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitisen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jaci.2013.11.012en_US
dc.identifier.scopus84901807832-
dc.contributor.authorscopusid35429595700-
dc.contributor.authorscopusid7103273891-
dc.contributor.authorscopusid34573859300-
dc.contributor.authorscopusid35355799700-
dc.contributor.authorscopusid7003526269-
dc.contributor.authorscopusid7004451212-
dc.contributor.authorscopusid55975832500-
dc.contributor.authorscopusid23036071200-
dc.contributor.authorscopusid6602633423-
dc.description.lastpage1614en_US
dc.identifier.issue6-
dc.description.firstpage1608en_US
dc.relation.volume133en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages7en_US
dc.utils.revisionen_US
dc.date.coverdateJunio 2014en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr4,869-
dc.description.sjrqQ1-
dc.description.scieSCIE-
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-3047-8908-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameCarrillo Díaz, Teresa-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

173
actualizado el 15-sep-2024

Citas de WEB OF SCIENCETM
Citations

159
actualizado el 15-sep-2024

Visitas

35
actualizado el 20-ene-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.